KRAS Inhibitor Resistance in <i>MET</i> -Amplified <i>KRAS</i> G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

Abstract

<i>MET</i> amplification leads to the development of resistance to <i>KRAS</i> ^G12C inhibitors in NSCLC. Dual blockade of MET and <i>KRAS</i> ^G12C could be a treatment option for <i>MET</i>-amplified, <i>KRAS</i> ^G12C-mutated NSCLC.